{"entity":{"id":"drew-weissman","kind":"person","name":"Drew Weissman","aka":[],"tldr":"Drew Weissman is the Nobel laureate whose modified-mRNA discovery underlies mRNA vaccines and now in vivo CAR-T.","summary":"Drew Weissman is the Roberts Family Professor in Vaccine Research and Director of the Penn Institute for RNA Innovation at the Abramson Cancer Center, University of Pennsylvania. He is the Nobel laureate who, with Katalin Karikó, discovered that nucleoside modification lets messenger RNA evade innate immune sensing, the finding behind mRNA vaccines, recognised with the Nobel Prize in 2023. His selected paper reports the suppression of RNA recognition by Toll-like receptors through nucleoside modification. His laboratory now works on targeted lipid nanoparticles, including in vivo T-cell engineering that seeded the company Capstan, with relevance to personalised mRNA cancer vaccines and in vivo CAR-T.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weissman%20D%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["neoantigen-mrna-vaccine","in-vivo-car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Roberts Family Professor in Vaccine Research; Director, Penn Institute for RNA Innovation","institutionId":"penn-abramson","specialisms":["mRNA therapeutics","Lipid nanoparticles","In vivo cell engineering"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weissman%20D%5BAuthor%5D"}],"papers":[{"title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","journal":"Immunity","year":2005,"url":"https://doi.org/10.1016/j.immuni.2005.06.008","doi":"10.1016/j.immuni.2005.06.008"}],"orcid":"0000-0002-1501-6510"},"route":"/people/drew-weissman/","neighbours":{"technology":[{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"institution":[{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/"}]}}